3-(benzylamino)-4-(cyclohexylamino)-n-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 analogues as cell death inhibitors for treating e.g. stroke

A compound depicted in formula (I)

• wherein
• R1 is selected from the group consisting of H and aryl-substituted C1-C4-alkyl;
• R2 is selected from the group consisting of H and aryl-substituted C1-C4-alkyl;
• R3 is selected from the group consisting of a C3-C12-cycloalkyl optionally substituted with one of more halogens, optionally replacing one or more carbons by heteroatoms in the cycloalkyl ring structure;
• R4 is selected from the group consisting of C1-C4-alkyl, wherein said C1-C4-alkyl is terminated with an R7 group wherein R7 is a C3-C10-heterocycle optionally substituted with one or more halogens;
• R5 is selected from the group consisting of H or C3-C12-cycloalkyl optionally substituted with one of more halogens, optionally replacing one or more carbons by heteroatoms in the cycloalkyl ring structure;
• and
• R6 is selected from the group consisting of H or a structure as defined in R4;
• and pharmaceutically acceptable salts thereof, and individual enantiomers and diastereomers thereof.